Each issue of Med Ad News delivers broad coverage and penetrating
analysis of the issues, events, trends, and strategies shaping the pharmaceutical
industry. Through a combination of industry expertise and extensive research,
our editors provide news content and analysis that is original, exclusive,
and proactive. We examine historical industry trends and current news to
provide objective insight into industry business and the marketing of medicines.
Med Ad News is read by senior management, marketing and sales
professionals, product and account managers, and R&D professionals
representing pharmaceutical, biotechnology, and medical device manufacturers,
health-care and general business companies, and marketing support agencies,
among others.
Because it offers reliable, compelling, and need-to-know information,
Med
Ad News has attracted a high-quality, loyal readership. A recent independent
survey among subscribers attests to how highly they value Med Ad News'
content.
--Nearly 50% have been subscribers for at least five years
--Seventy-four percent read three out of every four issues
--Subscribers spend an average of 42 minutes reading each issue
--On average, subscribers save their issues for almost eight months
--When asked which one industry publication (among four surveyed) they
would choose to receive if they could receive only one, they chose Med
Ad News by an overwhelming majority.
Our top subscribing companies are some of the industry’s bigest
names.
AstraZeneca, Wyeth, GlaxoSmithKline, Novartis, Pfizer Inc. Sanofi-Aventis
Bristol-Myers Squibb, Merck & Co., Abbott Laboratories, Amgen
Inc.
Eli Lilly and Co., Bayer, Schering-Plough, Genentech Inc., Johnson
& Johnson
Alcon Inc., Baxter, Genzyme, and more
|
